Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.
- Status
- NOT_YET_RECRUITING
- Phase
- NA
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- Status
- TERMINATED
- Phase
- PHASE2
Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Immunotherapy for Advanced Liver Cancer
- Status
- SUSPENDED
- Phase
- PHASE2/PHASE3
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2